Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 55-63

  Hung, Chao Hung ^a   Chen, Chien Hung ^a   Lu, Sheng Nan ^a   Wang, Jing Houng ^a   Hu, Tsung Hui ^a   Huang, Chao Min ^a   Tsai, Ming Chao ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Dual hepatitis B and C; Genotype; HBsAg seroclearance; Interferon; Precore core promoter mutation

Indexed keywords

ALPHA2B INTERFERON; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL THERAPY; ARTICLE; BASAL CORE PROMOTER MUTATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MUTATION RATE; PATIENT MONITORING; PRECORE PROMOTER MUTATION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRAL GENETICS; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COINFECTION; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; RIBAVIRIN; RISK FACTORS; YOUNG ADULT;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84355161524     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.10.018     Document Type: Article

References (49)

1. Brunetto M.R., Giarin M.M., Oliveri F., Chiaberge E., Baldi M., Alfarano A., Serra A., Saracco G., Verme G., Will H., Bonino F. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl. Acad. Sci. USA. 1991, 88:4186-4190.
2. Buckwold V.E., Xu Z., Chen M., Yen T.S., Ou J.H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 1996, 70:5845-5851.
3. Carman W.F., Jacyna M.R., Hadziyannis S., Karayiannis P., McGarvey M.J., Makris A., Thomas H.C. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989, 2:588-591.
4. Chan H.L., Hussain M., Lok A.S. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999, 29:976-984.
5. Chen C.H., Lee C.M., Lu S.N., Changchien C.S., Eng H.L., Huang C.M., Wang J.H., Hung C.H., Hu T.H. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J. Clin. Microbiol. 2005, 43:6000-6006.
6. Chen C.H., Hung C.H., Lee C.M., Hu T.H., Wang J.H., Wang J.C., Lu S.N., Changchien C.S. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007, 133:1466-1474.
7. Chen C.H., Lee C.M., Hung C.H., Hu T.H., Wang J.H., Wang J.C., Lu S.N., Changchien C.S. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int. 2007, 27:806-815.
8. Chen C.H., Lee C.M., Hung C.H., Wang J.H., Hu T.H., Changchien C.S., Lu S.N. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J. Gastroenterol. Hepatol. 2011, 26:461-468.
9. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
10. Chu C.M., Sheen I.S., Liaw Y.F. The role of hepatitis C virus in fulminant viral hepatitis in an endemic area of hepatitis A and B. Gastroenterology 1994, 107:189-195.
11. Chu C.J., Hussain M., Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002, 122:1756-1762.
12. Chu C.M., Yeh C.T., Lee C.S., Sheen I.S., Liaw Y.F. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J. Clin. Microbiol. 2002, 40:16-21.
13. Chuang W.L., Dai C.Y., Chang W.Y., Lee L.P., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Yu M.L. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir. Ther. 2005, 10:125-133.
14. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-1520.
15. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer. 1998, 75:347-354.
16. Hamasaki K., Nakata K., Nagayama Y., Ohtsuru A., Daikoku M., Taniguchi K., Tsutsumi T., Sato Y., Kato Y., Nagataki S. Changes in the prevalence of HBeAg-negative mutants hepatitis B virus during the course of chronic hepatitis B. Hepatology 1994, 20:8-14.
17. Hung C.H., Lu S.N., Wang J.H., Lee C.M., Chen T.M., Tung H.D., Chen C.H., Huang W.S., Changchien C.S. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J. Gastroenterol. 2003, 38:153-157.
18. Hung C.H., Lee C.M., Lu S.N., Wang J.H., Tung H.D., Chen C.H., Changchien C.S. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J. Gastroenterol. Hepatol. 2005, 20:727-732.
19. Hung C.H., Lee C.M., Lu S.N., Wang J.H., Chen C.H., Hu T.H. Hepatic steatosis with hepatitis B virus/hepatitis C virus dual infection. Hepatology 2010, 52:1521-1522.
20. Hung C.H., Lu S.N., Wang J.H., Hu T.H., Chen C.H., Huang C.M., Lee C.M. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually- infected patients. Antivir. Ther. 2011, 16:959-968.
21. Jardi R., Rodriguez F., Buti M., Costa X., Cotrina M., Galimany R., Esteban R., Guardia J. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001, 34:404-410.
22. Kao J.H., Chen P.J., Lai M.Y., Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554-559.
23. Kawabe N., Hashimoto S., Harata M., Nitta Y., Murao M., Nakano T., Shimazaki H., Arima Y., Komura N., Kobayashi K., Yoshioka K. The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection. J. Gastroenterol. 2009, 44:751-756.
24. Kurosaki M., Enomoto N., Asahina Y., Sakuma I., Ikeda T., Tozuka S., Izumi N., Marumo F., Sato C. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J. Med. Virol. 1996, 49:115-123.
25. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
26. Lee C.M., Lu S.N., Changchien C.S., Yeh C.T., Hsu T.T., Tang J.H., Wang J.H., Lin D.Y., Chen C.L., Chen W.J. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999, 86:1143-1150.
27. Lee C.M., Chen C.H., Lu S.N., Tung H.D., Chou W.J., Wang J.H., Chen T.M., Hung C.H., Huang C.C., Chen W.J. Prevalence of clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand. J. Gastroenterol. 2003, 1:95-101.
28. Liaw Y.F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995, 22:1101-1108.
29. Lin C.L., Kao J.H. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 2011, 26:123-130.
30. Liu C.J., Chen P.J., Lai M.Y., Kao J.H., Jeng Y.M., Chen D.S. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003, 37:568-576.
31. Liu C.J., Chuang W.L., Lee C.M., Yu M.L., Lu S.N., Wu S.S., Liao L.Y., Chen C.L., Kuo H.T., Chao Y.C., Tung S.Y., Yang S.S., Kao J.H., Liu C.H., Su W.W., Lin C.L., Jeng Y.M., Chen P.J., Chen D.S. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504.
32. Liu J., Yang H.I., Lee M.H., Lu S.N., Jen C.L., Wang L.Y., You S.L., Iloeje U.H., Chen C.J. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010, 139:474-482.
33. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., Lu Z.M., Piratvisuth T., Germanidis G., Yurdaydin C., Diago M., Gurel S., Lai M.Y., Button P., Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351:1206-1217.
34. Mizokami M., Nakano T., Orito E., Tanaka Y., Sakugawa H., Mukaide M., Robertson B.H. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett. 1999, 450:66-671.
35. Norder H., Hammas B., Lofdahl S., Couroucé A.M., Magnius L.O. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J. Gen. Virol. 1992, 73:1201-1208.
36. Okamoto H., Yotsumoto S., Akahane Y., Yamanaka T., Miyazaki Y., Sugai Y., Tsuda F., Tanaka T., Miyakawa Y., Mayumi M. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J. Virol. 1990, 64:1298-1303.
37. Okamoto H., Twuda F., Akahane Y., Sugai Y., Yoshiba M., Moriyama K., Tanaka T., Miyakawa Y., Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol. 1994, 68:8102-8110.
38. Okamoto H., Tsuda F., Sakugawa H., Sastrosoewignjo R.I., Imai M., Miyakawa Y., Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol. 1998, 69:2575-2583.
39. Raimondo G., Brunetto M.R., Pontisso P., Smedile A., Maina A.M., Saitta C., Squadrito G., Tono N. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B/hepatitis C virus-coinfected patients. Hepatology 2006, 43:100-107.
40. Ren X., Xu Z., Liu Y., Li X., Bai S., Ding N., Zhong Y., Wang L., Mao P., Zoulim F., Xu D. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J. Viral. Hepat. 2010, 17:887-895.
41. Sagnelli E., Coppola N., Scolastico C., Filippini P., Santantonio T., Stroffolini T., Piccinino F. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000, 32:1106-1110.
42. Stuyver L., De Gendt S., Van Geyt C., Zoulim F., Fried M., Schinazi R.F., Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J. Gen. Virol. 2000, 81:67-74.
43. Hepatitis C-global prevalence. Wkly. Epidemiol. Rec. 2002, 77:41-48. World Health Organization.
44. Yeh C.T. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir. Ther. 2010, 15:471-475.
45. Yeh C.T., Chiu C.T., Tsai S.L., Hong S.T., Chu C.M., Liaw Y.F. Absence of precore stop mutant in chronic dual (B and C) and triple (B, C, and D) hepatitis virus infection. J. Infect. Dis. 1994, 170:1582-1585.
46. Yeh C.T., Chu C.M., Liaw Y.F. Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. J. Gastroenterol. Hepatol. 1998, 13:131-136.
47. Yin J., Xie J., Liu S., Zhang H., Han L., Lu W., Shen Q., Xu G., Dong H., Shen J., Zhang J., Han J., Wang L., Liu Y., Wang F., Zhao J., Zhang Q., Ni W., Wang H., Cao G. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am. J. Gastroenterol. 2011, 106:81-92.
48. Yu M.L., Lee C.M., Chuang W.L., Lu S.N., Dai C.Y., Huang J.F., Lin Z.Y., Hu T.H., Chen C.H., Hung C.H., Wang J.H., Chen C.L., Kao J.H., Lai M.Y., Liu C.H., Su T.H., Wu S.S., Liao L.Y., Kuo H.T., Chao Y.C., Tung S.Y., Yang S.S., Chen P.J., Liu C.J., Chen D.S. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J. Infect. Dis. 2010, 202:86-92.
49. Zarski J.P., Bohn B., Bastie A., Pawlotsky J.M., Baud M., Bost-Bezeaux F., Tran van Nhieu J., Seigneurin J.M., Buffet C., Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses. J. Hepatol. 1998, 28:27-33.